ACLX
Arcellx Inc
NASDAQ: ACLX · HEALTHCARE · BIOTECHNOLOGY
$115.07
+0.00% today
Updated 2026-04-28
Market cap
$6.73B
P/E ratio
—
P/S ratio
302.04x
EPS (TTM)
$-4.07
Dividend yield
—
52W range
$48 – $115
Volume
2.8M
Arcellx Inc (ACLX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $17.91M | $110.32M | $107.94M | $22.29M |
| Revenue growth (YoY) | — | — | — | — | — | +515.9% | -2.2% | -79.4% |
| Cost of revenue | — | $326000.00 | $629000.00 | $1.04M | $2.22M | $2.04M | $5.19M | $6.68M |
| Gross profit | — | $-326000.00 | $-629000.00 | $-1.04M | $-2.22M | $110.32M | $102.75M | $15.61M |
| Gross margin | — | — | — | — | -12.4% | 100.0% | 95.2% | 70.0% |
| R&D | $6.11M | $15.77M | $25.06M | $46.88M | $149.56M | $133.85M | $157.09M | $157.61M |
| SG&A | $2.20M | $2.21M | $7.04M | $18.14M | $41.70M | $66.35M | $88.41M | $117.76M |
| Operating income | $-8.31M | $-17.97M | $-32.10M | $-65.02M | $-191.26M | $-89.88M | $-137.57M | $-253.08M |
| Operating margin | — | — | — | — | -1067.8% | -81.5% | -127.5% | -1135.6% |
| EBITDA | $-8.22M | $-17.65M | $-31.47M | $-63.98M | $-184.74M | $-64.14M | $-99.06M | $-197.97M |
| EBITDA margin | — | — | — | — | -1031.3% | -58.1% | -91.8% | -888.3% |
| EBIT | $-8.31M | $-17.97M | $-32.10M | $-65.02M | $-186.96M | $-66.19M | $-104.25M | $-204.65M |
| Interest expense | $0.00 | $0.00 | $0.00 | $49000.00 | $1.72M | $3.84M | $1.03M | $24.22M |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-8.31M | $-17.97M | $-32.09M | $-63.93M | $-188.68M | $-70.69M | $-107.35M | $-228.93M |
| Net income growth (YoY) | — | -116.3% | -78.6% | -99.2% | -195.1% | +62.5% | -51.9% | -113.3% |
| Profit margin | — | — | — | — | -1053.4% | -64.1% | -99.5% | -1027.3% |